SEC Form 4 · accession 0001012975-17-000867

Altimmune, Inc. · ALT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 17, 2017

Accepted (ET)

Nov 21, 2017 · 6:10 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001326190

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, par value $0.0001^F1	Nov 17, 2017	P	6,295	$2.121	A	227,999	D
Common Stock, par value $0.0001^F2	Nov 20, 2017	P	4,800	$2.0745	A	232,799	D
Common Stock, par value $0.0001^F3	Nov 21, 2017	P	7,236	$2.0599	A	240,035	D
Common Stock, par value $0.0001	holding	—	—		—	12,393	I	IRA

No Table II lines on this filing.

F1The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.11 to $2.15 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
F2The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.06 to $2.10 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
F3The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.03 to $2.08 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.